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Abstract
Epstein-Barr virus (EBV) is a human herpesvirus that persists as a largely subclinical infection in the vast majority of adults
worldwide. Recent evidence indicates that an important component of the persistence strategy involves active interference
with the MHC class I antigen processing pathway during the lytic replication cycle. We have now identified a novel role for
the lytic cycle gene, BILF1, which encodes a glycoprotein with the properties of a constitutive signaling G-protein-coupled
receptor (GPCR). BILF1 reduced the levels of MHC class I at the cell surface and inhibited CD8
+ T cell recognition of
endogenous target antigens. The underlying mechanism involves physical association of BILF1 with MHC class I molecules,
an increased turnover from the cell surface, and enhanced degradation via lysosomal proteases. The BILF1 protein of the
closely related CeHV15 c1-herpesvirus of the Rhesus Old World primate (80% amino acid sequence identity) downregulated
surface MHC class I similarly to EBV BILF1. Amongst the human herpesviruses, the GPCR encoded by the ORF74 of the KSHV
c2-herpesvirus is most closely related to EBV BILF1 (15% amino acid sequence identity) but did not affect levels of surface
MHC class I. An engineered mutant of BILF1 that was unable to activate G protein signaling pathways retained the ability to
downregulate MHC class I, indicating that the immune-modulating and GPCR-signaling properties are two distinct functions
of BILF1. These findings extend our understanding of the normal biology of an important human pathogen. The discovery
of a third EBV lytic cycle gene that cooperates to interfere with MHC class I antigen processing underscores the importance
of the need for EBV to be able to evade CD8
+ T cell responses during the lytic replication cycle, at a time when such a large
number of potential viral targets are expressed.
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Introduction
Viruses that persist asymptomatically in infected individuals
need to evade or modulate immune responses, and particularly the
adaptive T cell responses. A universal mechanism for virus
persistence involves latency, where viral genes are transcriptionally
silenced and, therefore, not available as targets for immune
effectors. In addition, viruses may exhibit active immune-evasion
mechanisms. In this context, the herpesviruses are paradigmatic.
For example, the human cytomegalovirus (HCMV, a b-herpesvi-
rus), encodes at least 25 proteins with immune-modulating
functions [1], of which 5 can impair antigen presentation via
MHC-class I to the CD8
+ T cell responses: US6 binds to the
transporter associated with antigen processing (TAP) complex to
inhibit peptide transport from the cytosol to the ER [2–4], US3
[5–7] and US10 [8] interfere with the maturation of MHC class I
heavy chains and their egress from the ER, while US2 and US11
trigger retrograde transport of MHC class I from the ER to the
cytosol with subsequent proteasome-mediated degradation [9–11].
Epstein-Barr virus (EBV) is a c1-herpesvirus whose normal
biology is fundamentally distinct from most other human
herpesviruses in that it has growth-transforming activity for
human B cells [12]. This provides an alternative strategy for
replicating virus genomes in proliferating cells without necessarily
producing infectious viral progeny. This is a potentially dangerous
strategy and it is unsurprising, therefore, that EBV is associated
with the pathogenesis of certain human cancers [12,13].
Nevertheless, EBV has evolved to persist asymptomatically in
most immunocompetent individuals, and it is ubiquitous in adult
populations worldwide. This successful persistence is largely
attributable to the ability of EBV to establish various types of
‘latency’ (i.e. not producing infectious virus progeny) in lymphoid
cells [14]. It is notable that the most restricted forms of latency
(which involve expression either of no viral genes, or of non-coding
small RNAs and possibly the poorly immunogenic EBNA1 and/or
LMP2A proteins) are normally associated with quiescent cells and
can evade recognition by CD8
+ T cells [12,14,15]. In contrast, the
form of latency associated with growth transformation is
PLoS Pathogens | www.plospathogens.org 1 January 2009 | Volume 5 | Issue 1 | e1000255characterized by expression of at least 8 viral proteins, including
immunodominant antigens [12,14,15], together with enhanced
expression of antigen presentation components [16,17] that render
the cells susceptible to recognition and elimination by EBV-
specific CD8
+ cytotoxic T cell responses in vivo [12,14,15]. The
increased incidence of EBV-associated B lymphoproliferative
disease in iatrogenically immunosuppressed transplant patients
[12,18] emphasizes the need for adaptive T cell immune responses
to prevent uncontrolled proliferation of EBV-transformed B cells.
While the interaction of EBV with the host immune responses
differs from non-oncogenic herpesviruses during the growth-
transforming phase of virus infection, it does share many
properties with non-oncogenic herpesviruses during the lytic virus
replication phase of the viral life-cycle. Responses to EBV lytic
cycle antigens dominate the EBV-specific T cell response in both
primary and persistent infection with the virus, but the ability of
CD8
+ T cells to recognize EBV-infected B cells in lytic cycle is
compromised by a reduced expression of cell surface MHC class I
[15,19,20]. The levels of cell surface MHC class I in lytic cycle
reflect active interference with the antigen processing pathway by
mechanisms that are poorly understood but which are at least in
part due to an impairment of TAP-dependent peptide transport
into the ER [21] and by host protein synthesis shutoff [22]. The
early lytic cycle genes, BNLF2a and BGLF5 were recently identified
as genes targeting TAP function [23] and host-shutoff [22,24]
respectively. While BGLF5 protein remains expressed throughout
lytic cycle, BNLF2a protein expression decreases within 24 hr of
induction and probably only acts during the early stages of lytic
cycle (N. Croft, D. Horst et al, manuscript in preparation).
In the present study, we have identified a third lytic cycle gene
that actively interferes with MHC class I antigen presentation to
CD8
+ T cells by increasing the turnover of MHC class I molecules
at the cell surface and targeting them for lysosomal degradation.
This new immune-evasion function of EBV mapped to BILF1,
which was previously identified as a rhodopsin-like seven-
transmembrane segment G-protein coupled receptor (GPCR)
with constitutive signaling functions [25–27]. We have character-
ized the molecular mechanisms by which BILF1 increases MHC
class I turnover, and found them to be independent of its G-
protein activating function and distinct from the mechanisms
employed by other herpesviruses that target MHC class I for
degradation.
Results
BILF1 affects MHC class I expression and antigen
presentation to CD8
+ T cells
We initiated a systematic screen of the EBV lytic genes to
identify viral products that might affect MHC class I expression.
EBV genes were cloned into the bicistronic vector pCDNA3-
IRES-nls-GFP, which co-expresses the inserted gene with GFP,
then transfected into 293 and MJS cells. At 48 h after transfection,
the cells were stained with PE-conjugated W6/32 mAb and the
levels of surface MHC class I molecules were measured by flow
cytometry. Representative results of W6/32 staining in transfected
293 cells are shown in Fig. 1A. As a negative control, ‘empty’
pCDNA3-IRES-nls-GFP vector was transfected, and as a positive
control, a known immune-evasion gene was transfected using the
pCDNA3-BNLF2a-IRES-nls-GFP vector. The results show that
the LF2, BMRF2, and BILF2 had no effect on MHC class I levels,
whereas BILF1 caused a reduction comparable to BNLF2a.I n
addition, two other EBV genes, LF1 and BXLF2 were also
screened in the same set of experiments and had no effect on
MHC class I levels (data not shown). This assay was then extended
to a second cell line (MJS) chosen for its expression of MHC class
II as well as MHC class I molecules, which confirmed the
downregulation of MHC class I by BILF1, with no effect on the
levels of MHC class II (Fig. 1B).
These screening experiments suggested a specific effect on
surface MHC class I expression by BILF1. To examine this in
more detail, we generated a retroviral expression vector for BILF1,
and transduced both 293 and MJS cells to generate stable cell lines
expressing BILF1. Since the BILF1 in these retroviral vectors
contained an N-terminal HA-tag sequence, expression of BILF1 in
the transduced cells was initially confirmed by staining of viable
cells with anti-HA mAb and flow cytometry analysis (data not
shown). Staining with PE-W6/32 mAb confirmed that expression
of MHC class I expression at the cell surface was reduced in
BILF1-expressing 293 and MJS cells relative to paired lines
transduced with a control retrovirus vector (Fig. 2A). This effect
was reproducibly stronger in the stable retroviral transduced cells
than in the previous transient-transfection experiments. No
downregulation of MHC class II in MJS, nor of transferrin
receptor (TfR) in 293 or MJS, was observed by flow cytometry
(data not shown). Western blots of whole cell lysates showed that
the effect of BILF1 on the levels of cell surface MHC class I were
reflected by a similar decrease in the amount of total cellular
MHC class I heavy chains (Fig. 2B). Notably, the levels of TAP-1
and TAP-2 components of the peptide transporter complex and
calregulin were unaffected by expression of BILF1 (Fig. 2B). Levels
of TfR receptor were unaffected in 293 cells but reproducibly
showed a small increase, along with MHC class II, in MJS cells
(Fig. 2B).
The aforementioned results raised the possibility that BILF1
might cause an impairment of the antigen processing pathway that
would affect antigen recognition by CD8
+ T cell responses. To test
this hypothesis, HLA-B8 positive MJS cells were transiently
transfected with p509 plasmid together with control pCDNA3-
IRES-nlsGFP vector or different amounts of pCDNA3-BILF1-
IRES-nlsGFP. The p509 vector expresses BZLF1, an EBV lytic
Author Summary
Epstein-Barr virus (EBV) is a herpesvirus and an important
human pathogen that can cause diseases ranging from
non-malignant proliferative disease to fully malignant
cancers of lymphocytes and epithelial cells. Nevertheless,
the vast majority of people in all populations worldwide
are infected with EBV. After primary infection the virus
persists for the life of the infected individual, and usually
without clinical symptoms. To understand how EBV causes
disease, we also need to know how this virus is able to
persist in healthy individuals with potent immune-
responses. A picture is emerging which suggests that
EBV, similar to non-tumorigenic herpesvirus, has multiple
co-operating mechanisms to modulate immune responses
by interfering with antigen processing pathway in cells
undergoing lytic virus replication. We have now identified
an EBV-encoded protein, BILF1, which targets MHC class I
molecules for lysosomal degradation, leading to impaired
recognition by immune T cells. BILF1 is a constitutively
active G-protein-coupled receptor, but its effect on MHC
class I degradation is independent of its signaling
functions, and the molecular mechanisms are distinct
from those identified in other viruses that induce
degradation of MHC class I. This work aids our under-
standing of EBV biology and emphasizes the complexity of
mechanisms evolved by viruses to enable persistent
infection.
EBV BILF1 Impairs Antigen Processing
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CD8
+ T cell effector clone. Following co-culture of RAK T cells
with the transfected MJS target cells, the release of IFN-c was
assayed by ELISA as a measure of T cell recognition. The
representative experiment in Fig. 3A shows that the RAK clone
did not respond to vector control transfected MJS, but showed
clear recognition of cells transfected with BZLF1. This recognition
was inhibited in a dose-dependent manner by co-transfection of
BILF1, exceeding 90% inhibition at the highest dose of pCDNA3-
BILF1-IRES-nlsGFP transfected. Similar results were obtained in
3 separate experiments. Western-blots of the transfected target
cells (.. 3B) showed that BILF1 protein expression increased with
increasing amounts of pCDNA3-BILF1-IRES-nlsGFP plasmid, as
expected. Interestingly, the amount of BZLF1 protein also showed
a smaller but reproducible concomitant increase in expression,
possibly as a result of constitutive BILF1 signaling (e.g. activation
of NFkB; see below) enhancing the CMV promoter driving BZLF1
expression in p509. A similar inhibition of EBV-specific CD8
+ T
cell recognition by BILF1 was observed in additional experiments
performed with 293 cells transfected with the BMLF1 target
recognized by HLA-A2 restricted T cell clones (data not shown).
In healthy infected individuals, EBV latency is established in the
B lymphocyte pool, which implies that at some stage lytic cycle
must occur in B cells for the virus to be transmitted to epithelial
cells or other hosts. We therefore examined the effect of BILF1
expression in B cells. To simplify the experiment, we chose to use
LCLs that had been established by infection of normal resting B
cells with a BZLF1 knock-out recombinant EBV; this provided us
with a range of endogenous latent proteins as target antigens in a
good antigen-presenting host cell which was unable to enter lytic
cycle and, therefore, unable to express BILF1 from the viral
genome. These LCL were transduced with a PLZRS-BILF1-
IRES-GFP retrovirus, and 6 days later were stained for surface
MHC class I and class II molecules with PE-conjugated
antibodies. The GFP positive (BILF1
+) population was shown by
flow cytometry to express almost 40% less surface MHC class I
compared to the GFP negative (BILF1
2) population in the same
culture (Fig. 4A). The expression of BILF1 did not affect the
expression of surface MHC class II molecules. The reduction in
the expression of surface MHC class I by BILF1 was smaller than
that seen in 293 and MJS cells (Fig. 2), but was reproducibly
observed in 3 experiments with two different LCLs.
To examine the functional significance of this BILF1-mediated
reduction of surface MHC class I expression, EBV-specific T cell
recognition experiments were performed on GFP
+ cells isolated on
a fluorescence activated cell sorter after transduction with either a
control retrovirus (PLZRS-IRES-GFP) or the BILF1 retrovirus
(PLZRS-BILF1-IRES-GFP). These cells were used as targets in T
cell assays with different effector cell clones specific for
constitutively-expressed latent EBV proteins. The representative
experiments in Fig. 4B show that CD8
+ effectors specific for one of
three different latent proteins (EBNA1, HLA-B35 restricted;
Figure 1. BILF1 identified as a lytic gene that downregulates surface MHC class I. 293 (A) or MJS (B) cells were transfected with different
EBV genes in the bi-cistronic vector, pCDNA3-IRES-nlsGFP. At 48 hr post-transfection, surface MHC class I was stained with PE-conjugated W6/32 mAb
and (in MJS only) MHC class II was stained with PE-conjugated anti-DR mAb, YE2/36-HLK. Two-colour flow cytometry was used to analyse staining in
the untransfected GFP
2 population, shown as the solid line histogram, and in the transfected GFP
+ population, shown as the dashed line histogram.
The grey histogram denotes background staining obtained with an isotype control PE-conjugated antibody.
doi:10.1371/journal.ppat.1000255.g001
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all recognized the BILF1-expressing LCLs less efficiently than the
control LCLs. In contrast, recognition of BHRF1 antigen by
HLA-DR4 restricted CD4
+ effectors was not significantly different
between the control and BILF1-expressing LCLs (Fig. 4B). Similar
results were obtained in 3 separate experiments.
Figure 2. Characterization of cells stably transduced with a BILF1 retroviral vector. (A) 293 or MJS cells were stably transduced with
control (pQCXIH) or BILF1 (pQCXIH-HABILF1) retrovirus. Surface MHC class I molecules were stained with PE-conjugated W6/32 antibodies and
analyzed by flow cytometry. The solid line histograms depict the surface HLA class I staining of control cell lines, while the dashed line histogram
depicts the surface HLA class I staining of cell lines expressing BILF1. The grey histogram illustrates background staining obtained with an isotype
control PE-conjugated antibody. (B) Total cell lysates were generated from the retrovirus-transduced 293 and MJS cell lines, and 2610
5 cell
equivalents were separated by SDS-PAGE and analyzed by Western Blotting with mAbs specific for BILF1 (3F10, anti-HA tag), MHC class I (HC10), MHC
class II (DA6.147), TAP-1 (148.3), TAP-2 (435.3), TfR (H68.4) or with polyclonal antibodies to calregulin as a loading control.
doi:10.1371/journal.ppat.1000255.g002
EBV BILF1 Impairs Antigen Processing
PLoS Pathogens | www.plospathogens.org 4 January 2009 | Volume 5 | Issue 1 | e1000255BILF1 decreases the half-life of newly-synthesised MHC
class I molecules
To further examine the mechanism of the effect of BILF1 on
MHC class I, we conducted a pulse-chase analysis of radio-labeled
molecules to study the fate of newly synthesized MHC class I
molecules. Control and BILF1
+ 293 cells were pulse-labeled with
35S-methionine/cysteine and chased at 37uC in medium contain-
ing cold methionine and cysteine. At each time point, cells were
lysed in NP40 detergent buffer and immunoprecipitated with mAb
W6/32, which reacts with properly assembled MHC class I
complexes.
In the first set of pulse-chase experiments, the immunoprecip-
tated MHC class I heavy chains were treated with endoglycosidase
H (Endo-H), an enzyme which deglycosylates newly-synthesized
heavy chains but not the mature form that has been exported from
the ER. Most MHC class I heavy chains were Endo-H-sensitive at
the beginning of the chase, as expected for newly synthesised
heavy chain in the ER. Within 30–60 min, nearly all heavy chains
became Endo-H-resistant. The rate of conversion of MHC class I
heavy chain to the Endo-H resistant form was similar in control
293 cells and in BILF1
+ 293 cells (Fig. 5A). These results indicate
that the export of MHC class I from the ER and its passage
through the Golgi is not impeded by BILF1, and that BILF1 most
probably acts at a later stage.
In order to compare the half life of MHC class I molecules, cells
were pulsed with radiolabel for 15 min, then chased for up to 8 h
before lysis and immunoprecipitation. As shown in Fig. 5B (upper
and middle panels), both MHC class I heavy chain and its
associated b2-microglobulin showed a half-life of around 8 h in
the control 293 cells, which was reduced to around 5 h in BILF1
+
293 cells. In the same experiment, immunoprecipitations of the
TfR showed no difference between control and BILF1
+ 293 cells
(Fig. 5B, lower panel).
It is worth noting that over a series of experiments the
incorporation of radiolabel into MHC class I molecules was not
reduced in BILF1-expressing 293 cells relative to the control cells,
indicating that BILF1 did not inhibit their translation.
Physical association of BILF1 with MHC class I complexes
In the pulse-chase and immunoprecipitation of MHC class I, an
additional co-precipitating band at around 33 kD was reproducibly
observed in W6/32 immunoprecipitates of BILF1-293 lysates but
not in control lysates (data not shown). To test the hypothesis that
this band might be the smaller, non-glycosylated, form of BILF1 co-
precipitating with MHC class I, we carried out a second round of
precipitations on eluates from the W6/32 precipitations. The
eluates were first diluted in lysis buffer, then equal aliquots were re-
precipitated either with a mAb to the HA-tag of BILF1 or with the
HC10 mAb to MHC class I free heavy chain. As shown in Fig. 6A,
re-precipitation of the W6/32 eluate from BILF1
+ 293 cells with
anti-HA revealed a band ataround 33 kDand a smearat 48–55 kD
(lane 2) that were not present in the re-precipitation with HC10
mAb (lane 4), and neither were they detectable in the anti-HA re-
preciptate of the control 293 sample (lane 1). These experiments
indicated that BILF1 associated with the MHC class I complex. It is
also worth noting that re-precipitation with HC10 mAb pulled
down a ladder of bands above the MHC class I heavy chain
(indicated with asterisks in Fig. 6A), which probably represent
ubiquitinated MHC molecules; the intensity of these bands was
indistinguishable between control 293 and BILF1
+ 293 cells.
To confirm the association of MHC class I with BILF1,
additional immunoprecipitations were conducted with lysates from
non-radiolabeled cells. Here, control 293 and BILF1
+ 293 cells
were again solubilized in NP40 detergent buffer, then immuno-
precipitated with W6/32 (MHC class I), anti-HA (BILF1), or anti-
TfR, before analysis by Western blotting. As shown in Fig. 6B,
some MHC class I molecules were co-precipitated by anti-HA
mAb (lane 6, top blot), and some BILF1 molecules were co-
precipitated by W6/32 mAb (lane 4, middle blot). In the control
TfR immunoprecipitations, no co-precipitation of MHC class I or
BILF1 was observed (lane 8, top and middle blots). Taken
together, the radiolabeled and cold immunoprecipitation data
provide compelling evidence that BILF1 physically associates with
the MHC class I molecules. Indeed, since weak co-precipitating
BILF1 bands were even seen immediately following a 15 min
pulse-label (data not shown), it is likely that the interaction first
occurs in the ER.
BILF1 is associated with MHC class I molecules on the cell
surface and increases their rate of internalization
For other viral proteins known to target MHC class I molecules
for degradation, three broad mechanisms have been identified:
either they induce retrograde transport from the ER to the cytosol
for degradation by proteasomes, as exemplified by HCMV US2
and US11 [9–11]; or they redirect them to endolysosomal vesicles
for degradation, exemplified by gp48 of murine CMV [28]; or
they trigger enhanced endocytosis of MHC class I from the cell
surface, followed by lysosomal degradation, as exemplified by K3
and K5 of KSHV [29].
Figure 3. BILF1 inhibits T cell recognition of endogenous EBV
antigen in MJS cells. (A) MJS cells were co-transfected with 0.02 mg
p509 plasmid (BZLF1 expression vector) and different amounts (0–2 mg)
of pCDNA3-HABILF1-IRES-nlsGFP bulked to a constant amount of DNA
with control plasmid. At 24 hr post-transfection, the MJS cells were co-
cultured with CD8
+ effector ‘RAK’ T cells for a further 18 hrs and the
supernatants were tested for the release of IFN-c as a measure of T cell
recognition. All results are expressed as IFN-c release in pg/ml and error
bars indicate standard deviation of triplicate cultures. (B) Total cell
lysates were generated from the above transfections, and 2610
5 cell
equivalents were separated and analyzed by Western Blotting using
antibodies specific for BZLF1, HA tag (BILF1), or calregulin as a loading
control.
doi:10.1371/journal.ppat.1000255.g003
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LCLs. (A) LCLs were transduced with PLZRS-HABILF1-IRES-GFP retrovirus. After 6 days, surface MHC class I was stained with PE-conjugated W6/32
mAb and MHC class II was stained with PE-conjugated anti-DR mAb, YE2/36-HLK. Two-colour flow cytometry was used to analyze staining in the
untransduced, GFP
2, population, shown as the solid line histogram, and in the transduced GFP
+ (BILF1
+) population, shown as the dashed line
histogram. The grey histogram denotes background staining obtained with an isotype control PE-conjugated antibody. (B) LCL cultures transduced
with control retrovirus or with the BILF1 retrovirus were sorted by flow cytometry to generate GFP
+/BILF1
2 and GFP
+/BILF1
+ lines to use as targets in
assays with EBV-specific T cells. The control and BILF1
+ LCL targets were incubated with HLA-matched CD8
+ effector T cells clones specific for EBNA1
(HPV), EBNA3A (YPL), or LMP2A (CLG) peptides, or a CD4
+ effector T cell clone specific for a BHRF1 (PYY) peptide. After 18 hrs the supernatants were
tested for the release of IFN-c as a measure of T cell recognition. All results are expressed as IFN-c release in pg/ml and error bars indicate standard
deviation of triplicate cultures.
doi:10.1371/journal.ppat.1000255.g004
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employed by BILF1, we first examined the cellular localisation of
BILF1. Confocal microscopy of BILF1-espressing 293 cells showed
that BILF1 was predominantly located in the plasma membrane
(Fig. 7A). Since antibodies to the HA-tag engineered to the N-
terminus of BILF1 allowed detection of BILF1 at the surface of
viable cells, we were able to examine whether the association
between MHC class I molecules and BILF1 can also be
demonstrated at the cell surface. Thus, viable control 293 and
BILF1
+ 293 cells were first incubated with W6/32 (MHC class I),
anti-HA (BILF1), or anti-TfR on ice to allow the antibodies to
bind to the surface antigen. After removal of excess unbound
antibodies by washing, the cells were then solubilized in NP40
detergent buffer and the antibody:antigen complexes precipitated
with protein A/G beads. As shown in Fig. 7B, some MHC class I
molecules were co-precipitated by anti-HA mAb (sample 4, upper
blot), and some BILF1 molecules were co-precipitated by W6/32
mAb (sample 2, lower blot). In the control TfR immunoprecip-
itations, no co-precipitation of MHC class I or BILF1 was
observed (sample 6).
We next asked whether BILF1 enhances the endocytosis of
surface MHC molecules. In MJS cells, BILF1 substantially
increased the rate of disappearance of MHC class I molecules
from the cell surface, but did not affect the rate of disappearance of
MHC class II molecules (Fig. 7C). Similar results were obtained
with LCLs that had been transduced with a BILF1 retrovirus (data
not shown). In 293 cells, expression of BILF1 reproducibly
increased the rate of disappearance of MHC class I molecules
from the cell surface, although the magnitude of the effect was
masked by the unusually high rate of disappearance in the control
293 cells (Fig. 7D, upper graph). Importantly, the rate of
Figure 5. Effect of BILF1 on maturation and degradation of
MHC class I molecules. (A) Acquisition of endoglycosidase H (Endo
H) -resistance of MHC class I heavy chain. 293 cells (2610
6) stably
transduced with control or BILF1 retrovirus were metabolically labeled
for 15 min with
35S-methionine/cysteine and chased for the indicated
time periods. After lysis in NP-40 detergent buffer, samples were
immunoprecipitated with mAb W6/32 and treated with Endo H
enzyme. Protein samples were separated by 10% acrylamide SDS/PAGE
gel, dried and exposed to autoradiography. (B) Kinetics of MHC class I
molecule degradation. 293 cells (2610
6) stably transduced with control
or BILF1 retrovirus were metabolically labeled for 15 min and chased for
the indicated time periods. After lysis in NP-40 detergent buffer,
samples were immunoprecipitated with mAb W6/32 (HLA class I heavy
chain and b2-microglobulin) or H68.4 (TfR). Protein samples were
separated by 10% SDS/PAGE gel, dried and exposed to autoradiogra-
phy.
doi:10.1371/journal.ppat.1000255.g005
Figure 6. BILF1 is physically associated with the MHC class
molecule complex. (A) 293 cells (10
7) stably transduced with control
(C) or BILF1 (B) retrovirus were metabolically labeled for 15 min and
chased for 20 min. After lysis in NP-40 buffer and immunoprecipitation
with mAb W6/32, the samples were dissociated by boiling in reducing
sample buffer, and were re-precipitated with either 3F10 ( HA tag on
BILF1) or HC10 (MHC class I heavy chain). Protein samples were
separated by 10% acrylamide SDS/PAGE gel, dried and exposed to
autoradiography. The arrowhead and bracket indicate the presence of
33 kD and 45–55 kD BILF1 bands, whilst the asterisks indicate probable
ubiquitinated MHC class I species. (B) 293 cells (2610
6)s t a b l y
transduced with control (C) or BILF1(B) retrovirus were treated with
concanamycin A (50 nM) for 20 hr prior to lysing the cells with NP40
detergent buffer and immunoprecipitation with antibodies specific for
MHC class I (W6/32), HA tagged BILF1 (12CA5), or TfR (H68.4). Cell
lysates and immune complexes were separated by SDS/PAGE gel, and
analyzed by western blotting using antibodies specific for MHC class I
(HC10), HA tagged BILF1 (3F10), and TfR (H68.4). The first two samples
on the gel are total cell lysates representing 5% of the input lysate for
immunoprecipitations.
doi:10.1371/journal.ppat.1000255.g006
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identical for the first 30 min of analysis; thereafter, the appearance
of new MHC class I molecules reached a plateau in BILF1
+ cells,
while new molecules continued to accumulate for at least a further
30 min in control 293 cells (Fig. 7D, lower graph). We interpret
the differences between control and BILF1 cells in these latter
experiments to be due to the effect of the increased rate of
internalisation of MHC class I molecules that becomes apparent
after 20–30 min (see Fig. 7D, upper graph). Together, the results
in Fig. 7A–D suggest that BILF1 targets the mature MHC class I
complexes for degradation after they reach the cell surface.
Lysosomal inhibitors block BILF1-induced degradation of
MHC class I
We used a panel of inhibitors to identify the mechanism of
BILF1-induced degradation of MHC class I molecules, including:
bafilomycin A1 and concanamycin A, which can inhibit
proteolysis by raising endolysosomal pH [30,31]; leupeptin, which
inhibits cysteine and serine proteases [32]; and the proteasome
inhibitor, MG132 [33]. Control and BILF1
+ 293 cells were
incubated with or without these inhibitors for 20 hr before
harvesting the cells for Western blot analysis. The representative
blot probed with HC10 in Fig. 8A shows that bafilomycin A1,
concanamycin A, and leupeptin all restored the level of MHC class
I heavy chains in BILF1-293 cells to the same levels seen in
control-293. The blots from three independent experiments were
quantitated by densitometry, and the mean values shown in the
histogram beneath the blot in Fig. 8A.
Fluorescence microscopy of BILF1
+ cells treated with lysosomal
inhibitors revealed a marked accumulation of intracellular MHC
class I staining that was not observed in BILF1
2 cells treated with
lysosomal inhibitor (Fig. 8B), nor in BILF1
+ cells treated with the
proteasome inhibitor, MG132 (data not shown). Furthermore,
quantitation of the total cell MHC class I protein in Western blots
revealed that the BILF1
+ 293 cells retained their overall reduced
expression of MHC class I molecules relative to control 293 cells
following treatment with the proteasome inhibitor (Fig. 8C).
Taken together, the results in Figs. 7 and 8 suggest that the
accelerated degradation induced by BILF1 occurs within an
endolysosomal compartment following internalisation of MHC
class I complexes from the cell surface.
Comparison of BILF1/GPCR homologs
It is well established that many, if not all, herpesviruses encode
proteins with features of GPCRs [27]. The most closely related
vGPCR to BILF1 amongst the human herpesviruses is the ORF74
product of KSHV (a c2-herpesvirus), which shares just 15% amino
acid sequence identity and 29.7% similarity with BILF1 (Fig. 9A).
However, a more closely related herpesvirus , CeHV15 (a c1-
herpesvirus, as is EBV), of the Rhesus Old World primate encodes
a BILF1 homolog sharing 80.4% amino acid sequence identity
and 88.5% similarity with EBV BILF1 (Fig. 9A).
Figure 7. BILF1 associates with MHC class I molecules at the cell surface and increases their rate of internalization. (A) BILF1 is
predominantly localized at the cell surface. 293 cells stably transduced with BILF1 retrovirus were grown on glass slides, fixed and permeabilized, then
stained with rat anti-HA (3F10) primary antibodies and Alexa FluorH 594 goat anti-rat IgG. The nuclei were counterstained with DAPI. The stained
slides were analyzed with a laser scanning confocal microscope, and the three photographs show different 1 micron-thick sections through
representative cells. BILF1 stained red, and the nuclei stained blue. (B) BILF1 and MHC class I molecules co-precipitate at the cell surface. 293 cells
(2610
6) stably transduced with control (C) or BILF1 (B) retrovirus were incubated with saturating concentrations of antibodies specific for MHC class I
(W6/32), TfR (H68.4) or HA tagged BILF1 (3F10) on ice. After washing away excess antibody, the cells were lysed with NP40 detergent buffer, then
precipitated with protein A/G beads and subjected to western-blotting as in Fig. 6B, using antibodies specific for MHC class I (HC10) and HA tagged
BILF1 (3F10). (C) BILF1 increases the rate of internalization of MHC class I, but not class II, from the cell surface. MJS cells stably transduced with
control or BILF1 retrovirus were incubated at 0uC with saturating concentrations of mAb to MHC class I (W6/32; top graph) or MHC class II (L234;
bottom graph), then washed and incubated at 37uC for different periods of time. The cells were subsequently stained with PE-conjugated goat anti-
mouse IgG antibody, and analyzed by flow cytometry. The mean fluorescence intensities of staining were averaged for triplicate samples, and
normalized to the initial time 0 min samples. (D) BILF1 increases the rate of internalization, but not the rate of appearance, of MHC class I at the cell
surface. Top graph: 293 cells stably transduced with control or BILF1 retrovirus were incubated at 0uC with saturating concentrations of mAb to MHC
class I (W6/32), then treated exactly as for the internalization assay performed with MJS cells in panel C. Bottom graph: replicate aliquots of the
saturated W6/32-bound cells were harvested at the indicated time points, and the appearance of new MHC class I molecules was assayed by staining
with PE-conjugated W6/32 antibody. The mean fluorescence intensities of staining were averaged for triplicate samples.
doi:10.1371/journal.ppat.1000255.g007
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BILF1 the ability to downregulate MHC class I, we cloned them
into the bicistronic vector pCDNA3-IRES-nls-GFP and transient-
ly transfected them into 293 and MJS cells, and analysed their
effect on cell surface MHC class I expression exactly as in Fig. 1.
The results illustrated by a representative experiment in Fig. 9B,
show that Rhesus CeHV15-BILF1 clearly did reduce MHC class I
expression at the cell surface, but that KSHV-ORF74 did not.
Figure 8. Lysosomal inhibitors block BILF1-enhanced degradation of MHC class I. (A) 293 cells stably transduced with control- (C) or BILF1-
(B) retrovirus were treated with or without Bafilomycin A1, concanamycin A, or leupeptin for 20 hr. Lysates from 2610
5 cell equivalents were
separated by SDS/PAGE gel, and analyzed by western blotting using antibodies specific for MHC class I (HC10) and calregulin. The blot is one
representative of three independent experiments. The histogram shows the mean results (6S.D.) of quantification by densitometry of all the blots
from 3 independent experiments, where the densities of the HC10 bands were normalized relative to their own calregulin loading control. (B) 293
cells stably transduced with control or BILF1 retrovirus were treated with concanamycin A (50 nM) for 6 hr prior to fixation and permeabilization with
methanol/acetone, then stained with W6/32 primary antibodies and Alexa FluorH 488 goat anti-mouse IgG secondary antibodies. The photographs
were obtained with a conventional fluorescence microscope. (C) 293 cells stably transduced with control (C) or BILF1 (B) retrovirus were treated with
or without the proteasome inhibitor, MG132, for 20 hr, and analyzed by western blot as in panel A. The additional, lower molecular weight species
detected is probably deglycosylated and/or partially degraded free heavy chain that is normally targeted for proteasomal degradation.
doi:10.1371/journal.ppat.1000255.g008
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of its signaling function
Since different vGPCRs activate different G-proteins and
signalling pathways, the results in Fig. 9 could be interpreted as
indicating that shared signalling functions of the EBV and
CeHV15 vGPCRs determine their ability to downregulate
MHC class I. To test this hypothesis, we obtained a signaling-
negative mutant of EBV BILF1. The BILF1 polypeptide contains
an EKT sequence in its predicted third transmembrane domain,
which represents a conservative amino acid substitution of the
‘DRY box’ (i.e. residues with acidic, basic, polar side chains),
known to be important in G-protein signaling [27,34]. Substitution
of an alanine for lysine at residue 122 abolished G-protein
activation and BILF1 signaling function, as we observed by
Figure 9. The ability of BILF1 homologs to downregulate MHC class I. (A) Multiple sequence alignment of EBV-BILF1, the rhesus
lymphocryptovirus CeHV15-BILF1, and KSHV-ORF74. The alignment was done with ClustalW version 1.8, and shading was done with Boxshade
version 3.21, available at http://www.ch.embnet.org/software/BOX_form.html. (B) 293 or MJS cells were transfected with EBV-BILF1, CeHV15-BILF1 or
KSHV-ORF74 genes in the bicistronic vector, pCDNA3-IRES-nlsGFP. At 48 hr post-transfection, surface MHC class I molecules were stained and
analyzed exactly as in Fig. 1.
doi:10.1371/journal.ppat.1000255.g009
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HEK293-NFkB reporter line. The results in Fig. 10A are the
mean of three independent experiments, and show that whereas
transfection of wt-BILF1 typically induced more than a 5-fold
increase in NFkB activity relative to the empty vector control
transfectant, the K122A-BILF1 mutant did not induce any
discernable NFkB activation above the vector control. In both
293 and MJS cells, transient transfection of the mutant K122A-
BILF1 was able to cause downregulation of MHC class I (Fig. 10B).
These results suggest that the ability of BILF1 to target MHC class
I molecules for endolysosomal degradation is not critically
dependent upon its signaling function.
Discussion
In this study we have shown that the BILF1 protein, which was
recently identified as a constitutive signaling vGPCR [25,26], can
downregulate cell surface MHC class I and abrogate EBV-specific
T cell recognition. The essential elements of the mechanism of this
immune evasion function have been elucidated. Pulse–labeling
and immunoprecipitation experiments with BILF1-transduced
cells revealed that BILF1 associates with MHC class I molecules
within 15 mins of biosynthesis. The MHC class I molecules can
mature to the Endo H-resistant glycosylated form as normal, but
were more rapidly internalized from the cell surface and were
degraded by lysosomal enzymes. The effects of BILF1 on MHC
class I were not critically dependent upon the activation of G-
protein signaling, and were not exhibited by the most closely
related human herpesvirus GPCR homolog, the ORF74 protein of
KSHV, which has 15% amino acid sequence identity with EBV
BILF1. Interestingly, the BILF1 homolog of a Rhesus c1-
herpesvirus (CeHV15 BILF1, showing 80% amino acid identity
with EBV BILF1) did downregulate MHC class I similarly to EBV
BILF1. This observation reinforces the degree of similarity in the
sequences and functions of the EBV and CeHV15, and
strengthens the case for CeHV15 infection of Rhesus Macaques
being an excellent animal model for understanding the interplay
between immune responses and virus-infected cells during
persistence of the virus in the healthy host and the development
of virus-induced tumors [23,35,36].
Our in vitro studies, identifying a new function for BILF1, add to
the complexity of the immune-evasion mechanisms of Epstein-
Barr virus during lytic replication. EBV has now been demon-
strated to target the MHC class I antigen processing pathway at
the level of translation, through BGLF5 [22,24]; peptide transport,
through BNLF2a [23]; and by targeting mature MHC class I
molecules for degradation, through BILF1. BGLF5 and BNLF2a
are both products of early lytic cycle genes [24,37], but there are
conflicting reports on the early/late status of BILF1 [25,26,37].
Our own results (D. van Leeuwen, unpublished) show that
induction of BILF1 mRNA expression during lytic cycle is
insensitive to phosphonoacetic acid treatment, indicating that it
is an early gene, although its appearance is delayed relative to
BNLF2a transcripts. The temporal expression of BNLF2a, BGLF5
and BILF1 proteins and their impact at different points along the
antigen processing pathway, suggest that their cooperative effects
will cause efficient abrogation of antigen presentation, particularly
at the later stage of lytic cycle. This is consistent with the
observation that CD8
+ T cell responses to late lytic cycle antigens
are rare compared to the responses to immediate-early and early
antigens [20]. It has also been suggested that the viral IL-10
homolog (vIL-10) produced by the BCRF1 gene might be involved
in evasion from CD8
+ T cell responses since vIL-10 can selectively
reduce levels of TAP-1 mRNA, and therefore peptide transport, in
human B cells [38]. However, since BCRF1 is a late gene, any
autocrine effects of vIL-10 on TAP-1 mRNA would be masked by
the earlier expression of the host-shutoff protein, BGLF5 [22,24].
In the context of immune-evasion, it is likely that secreted vIL-10
may be more relevant to bystander B cells being infected by the
virus released from cells undergoing lytic replication in vivo,
coupled with the effects of vIL-10 on T cell and NK cell functions.
BILF1 is a seven transmembrane segment GPCR which, like
many vGPCRs encoded by herpesviruses, shares structural and
functional characteristics with chemokine receptors [25–27]. One
role of viral chemoreceptors is to contribute to efficient lytic
replication cycle by reprogramming the host cell through multiple
signaling pathways [27], a process that might aberrantly lead to
cellular transformation and oncogenesis, as has been suggested for
KSHV ORF74 [39–41]. In addition, it has long been recognized
that viral chemoreceptors have the potential to contribute to
immune-evasion strategies. For example, Bodaghi and colleagues
reported in 1998 that one of the four vGPCRs of HCMV, encoded
by US28, can modify the chemokine environment of infected cells
by binding and internalizing MCP-1 (monocyte chemoattractant
protein) and RANTES (regulated on activation, normal T cell
expressed and secreted) to efficiently sequester these chemokines.
In certain cellular contexts, i.e. latent infection of monocytes with
HCMV, US28 can also transcriptionally upregulate MCP-1
Figure 10. BILF1 signaling function is not required to
downregulate MHC class I. (A) Wild-type or K122A-mutant BILF1
expression plasmids were transfected into the HEK293-NFkB reporter
cell line, and the degree of NFkB activation measured by detection of
luciferase activity. The results are the mean6S.D. for three independent
experiments performed in triplicate. (B) 293 and MJS cells were
transfected with wild type BILF1 or mutant K122A-BILF1 genes in the
bicistronic vector, pCDNA3-IRES-nlsGFP. At 48 hr post-transfection,
surface MHC class I molecules were stained and analyzed exactly as
in Fig. 1.
doi:10.1371/journal.ppat.1000255.g010
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transcription of MCP-1 is downregulated [43], though not by
US28. Similarly to HCMV US28, the U51 GPCR of HHV6 is
also able to bind and sequester RANTES and MCP-1, but the
HHV6 U51 additionally induces transcriptional downregulation of
RANTES [44]. These examples of transcriptional regulation of
immune-modulating chemokines by vGPCRs of b-herpesvirus are
likely to be more significant in the lytic cycle of this virus
subfamily, where host protein synthesis shutoff is not a feature of
lytic cycle as it is in a- and c-herpesviruses [22].
Our observation with BILF1 represents the first example of a
viral GPCR/chemokine receptor interfering directly with the
MHC class I antigen processing pathway. Interestingly, a similar
phenomenon was recently reported for the cellular chemokine
receptor, CXCR4 [45]. Thus, CXCL12 ligand-induced activation
of CXCR4 on malignant cancer cell lines and peripheral blood
mononuclear cells triggered down-regulation of MHC class I from
the cell surface. Mechanistically, this process involves physical
association of CXCR4 with the b2-microglobulin component of
mature MHC class I complexes, ubiquitination of the MHC class I
heavy chain, and endocytosis of MHC complexes into a late
endosomal/lysosomal compartment where degradation presum-
ably occurs. Although BILF1 is unable to directly associate with
b2-microglobulin (JZ, unpublished data) and we have no evidence
that BILF1 induces ubiquination of MHC class I heavy chains
above the levels seen in control BILF1
2 cells (Fig. 6), CXCR4 does
share some broad features with the mechanism by which BILF1
downregulates MHC class I, which raises the possibility that
targeting of the antigen processing pathway might not be a
property uniquely associated with the c2-herpesvirus BILF1
vGPCRs. It is perhaps relevant that when co-expressed in the
same cell, BILF1 and CXCR4 show almost complete co-
localization (both being present predominantly in the plasma-
membrane), whereas the KSHV-ORF74 and HCMV-US28
vGPCRs (predominantly intracellular) exhibit separate localiza-
tions to BILF1 [25].
Many other viral gene-products have been shown to target
MHC class I molecules for degradation. Some, such as the US3,
US10, US2 and US11 proteins of HCMV, target MHC molecules
before they reach the cell surface, either by interfering with the
maturation of MHC class I molecules and their egress from the
ER [5–8] or by inducing retrograde transport from the ER to the
cytosol with subsequent degradation by proteasomes [9–11].
Other viral proteins, such as the KSHV K3 and K5 proteins
[29,46,47], induce endocytosis and lysosomal degradation of cell
surface MHC class I complexes. Although BILF1 shares no
obvious structural or sequence properties with any of these viral
proteins, the mechanism of interference with MHC class I by
BILF1 shares many features with those proteins that induce
endocytosis of cell surface MHC class I molecules and subsequent
degradation. However, whereas, KSHV K3 and K5 proteins were
shown to induce ubiquitination of MHC class I heavy chains,
which appears to be a signal for endocytosis and subsequent
degradation [48,49], we found no evidence that BILF1 induced
ubiquitination of MHC class I heavy chains above the level seen in
control BILF1-negative cells. Furthermore, BILF1 lacks a plant
homeodomain (PHD) or RING-finger motif present in K3 and K5
proteins that are necessary for their ability to induce ubiquitination
of MHC class I molecules [49–51].
Some viral proteins, such as murine CMV gp48 [28] and the
HHV-6A/B U21 proteins [52], contain dileucine motifs in their
cytosolic C-terminus that have been shown to be important for
lysosomal targeting of MHC class I complexes, but no dileucine
motif is present in the cytosolic domains of BILF1. The HIV-1 Nef
protein contains a typical di-leucine motif that is involved in the
binding of adapter proteins involved in membrane trafficking
[53,54], although mutation of this motif does not affect the ability
of Nef to downregulate MHC class I [55]. Indeed, although Nef
was one of the first viral proteins reported to induce endocytosis
and degradation of MHC class I molecules from the cell surface
[56], it is now unclear to what extent endocytosis of MHC class I
accounts for its downregulation by Nef. An alternative explanation
is that Nef acts predominantly by diverting intracellular MHC
class I complexes to endosomes and lysosomes before they can
reach the plasma-membrane [57–59]. This would make Nef more
similar to murine CMV gp48 which also diverts MHC class I from
the ER to the lysosomal compartment for degradation [28].
Since BILF1 is predominantly located in the plasma membrane,
our data on BILF1 suggest that endocytosis of surface MHC class I
molecules associated with BILF1 is likely to be the main
mechanism of targeting the MHC class I molecules to the
lysosome. However, we cannot yet rule out the possibility that
some MHC class I molecules might also be diverted before they
reach the surface. An investigation of what adaptor molecules can
associate with BILF1 will provide crucial information to elucidate
the finer details of BILF1’s mechanism of action. It also remains to
be determined what are the sequence elements of BILF1 that are
involved in its association with MHC class I molecules.
Experiments are ongoing to resolve these unanswered questions.
It is perhaps surprising that BILF1 can inhibit T cell recognition
so efficiently when it has a comparatively small effect on the levels
of surface MHC class I (see Figs. 2–4). There are a number of
possible explanations for this. First, BILF1 might target different
HLA alleles with different efficiency. Thus, while HLA-A2, -B8,
and B35 might be efficiently removed from the cell surface for
degradation, other alleles recognized by W6/32 antibody may be
unaffected and will mask the full extent that selected MHC
molecules are being degraded. Secondly, the association of BILF1
with MHC class I molecules in the ER might interfere with
Tapasin or TAP binding and thus interfere with correct peptide
loading, while stabilizing a defective MHC complex and allowing
egress from the ER. Thirdly, the association of BILF1 with MHC
class I molecules at the cell surface might directly interfere with
recognition by TCR. None of these possibilities is mutually
exclusive, and further work is ongoing to test them.
In summary, through identifying and partially characterizing
the molecular mechanisms of an immune-evasion function for
BILF1, we have extended our understanding of the normal
biology of an important human pathogen. The discovery of a third
EBV lytic cycle gene that cooperates to interfere with MHC class I
antigen processing underscores the importance of the need for
EBV to be able to evade CD8
+ T cell responses during the lytic
replication cycle, at a time when such a large number of potential
viral targets are expressed.
Materials and Methods
Plasmids and retroviral expression vectors
The EBV lytic genes BMRF2, BILF1, BILF2, and BXLF2 were
PCR-amplified from the B95.8 virus sequences, and LF1 and LF2
from Raji EBV sequences, within the Bacterial artificial Chromo-
some (BAC) plasmid, 2089 [60]. The KSHV gene ORF74 was
PCR-amplified from a KSHV BAC [61]. The BILF1 homolog of a
Rhesus lymphocryptovirus was PCR-amplified from a cosmid
derived from the CeHV15 virus, [62] that was kindly provided by
F. Wang (Harvard Medical School, Boston). All the viral genes
were subcloned into the EcoRI/NotI sites of pCDNA3-IRES-nls-
GFP vector with an additional 59-HA tag. All plasmids were
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with 39-HA tag in pCDNA3-IRES-nls-GFP vector has been
described previously [23]. Expression plasmids p509, containing
the EBV BZLF1 gene, and pCEP4-SM, containing the EBV
BSLF2/BMLF1 spliced gene, have been described previously [24].
Two retroviral vector systems were used. The Retro-X
TM
Universal Packaging System (Clontech Laboratories, Inc.) was
used to prepare retrovirus based on the PQCXIH vector for
hygromycin drug selection. The alternative vector, pLZRS-IRES-
GFP, instead allowed coexpression of the marker gene GFP. The
BILF1 gene with a 59-HA tag was subcloned into each vector.
Cells and transfections
The HEK293 epithelial cell line (American Type Culture
Collection) and derived cell lines were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% fetal
bovine serum and penicillin-streptomycin antibiotics. The
HEK293-NFkB-luc cell line (kindly provided by G. Lipford,
Munich) contained a stably transfected NFkB-luciferase promoter-
reporter gene [63], and was maintained in medium supplemented
with 0.7 mg/ml G418 as a selective agent. The MJS (Mel JuSol)
melanoma-derived cell line [64] was maintained in RPMI-1640
medium supplemented with 10% fetal bovine serum and
penicillin-streptomycin antibiotics. 293 and MJS cell lines
transduced by PQCXIH-based retroviruses were maintained in
their medium with 400 mg/ml hygromycin. For some experi-
ments, 293 and MJS cells were transiently transfected with plasmid
DNA using Lipofectamine 2000 (Invitrogen). EBV specific CD8
+
cytotoxic T cells were grown in 10% FCS in RPMI-1640 medium
supplemented with 30% supernatant from the IL-2-producing
MLA 144 cell line [65] and 50 U/ml recombinant IL-2 as
described elsewhere [20].
Retroviral infection
For the transduction of 293 cells and MJS cells, the packaging
cell line (GP2-293) was transfected with retroviral vectors
(PQCXIH or PQCXIH-BILF1) and PVSV-G to produce
replication-defective viral particles. The supernatants containing
recombinant retrovirus were harvested 48 hours after transfection,
and filtered through a 0.22-mm pore, low protein-binding filter. To
generate stable cell lines by transduction with PQCXIH-BILF1 or
control PQCXIH-BILF1 retrovirus, 293 cells or MJS cells were
infected with 1 ml retrovirus supernatants with polybrene added to
4 mg/ml final dilution. The stable cell lines were selected by
400 mg/ml hygromycin.
For retrovirus transduction of LCLs, the packaging cell line
(GP2-293) was transfected with retroviral vectors (PLZRS-IRES-
GFP or PLZRS-BILF1-IRES-GFP) and PVSV-G to produce
replication-defective viral particles. To generate stable cell lines by
transduction with these viral vectors, the LCLs were infected with
retrovirus supernatants and the GFP
+ cells were sorted on a
Cytomation MoFlo cell sorter at 72 hr post-infection.
Antibodies
The BZ.1 murine mAb specific for the EBV BZLF1 encoded
protein was generated in the authors’ laboratory [66]. Murine
mAbs used to detect human MHC class I were: W6/32 [67] which
recognizes native b2m-associated MHC class I (HLA-A, -B, and -
C alleles) complexes; and HC10 [68], recognizing free HLA class I
heavy chains. The DA6.147 murine mAb specific for HLA-DR a-
chains was obtained from the ATCC, and mAb L234 [69] specific
for HLA-DR b-chains, was kindly provided by P. Cresswell
(Howard Hughes Medical Institute, New Haven). For flow
cytometry experiments, antibodies for detecting MHC class I
and class II were purchased from Serotec, including phycoery-
thrin(PE)-conjugated anti-HLA A,B,C (MCA81PE; clone W6/32)
andPE-conjugated anti-HLA DR (MCA71PE; clone YE2/36-
HLK). The murine mAbs specific for the TAP1, 148.3 [70], and
TAP2, 435.3, were kindly provided by R. Tampe (Wolfgang
Goethe-University, Frankfurt) and by P.M. van Endert (Institute
Necker, Paris) respectively. The murine mAb, H68.4, to human
transferrin receptor (TfR) protein was purchased from Roche
Diagnostics, and Goat antibodies to calregulin (sc6467) were
purchased from Santa Cruz Biotechnology. Rat mAb, 3F10, and
mouse mAb, 12CA5, directed against the influenza virus derived
HA tag, were purchased from Roche Diagnostics and Santa Cruz
Biotechnology respectively.
Flow cytometry analysis of cell surface MHC molecules
Cell surface expression of MHC class I on viable cells was
determined by staining with PE-labeled W6/32 antibodies or PE-
labeled isotype control mAb (both from Serotec) and detection on
a Beckman Coulter XL flow cytometer. The data were analysed
using Flowjo software (Tree Star).
To assay the kinetics of internalization of surface MHC class I
and class II molecules, 293 cells or MJS cells were incubated for
60 min on ice with saturating amounts of W6/32 or L234 mAb,
then washed three times in phosphate-buffered normal saline
(PBS) and replaced in warm culture medium and incubated at
37uC for the length of time indicated in the results section. To
terminate MHC/antibody complex internalization, cells were
rapidly cooled to 0uC. Finally, the mAb-bound surface MHC
molecules were stained at 0uC with PE-conjugated goat anti-
mouse IgG2a antibody (Serotec), and cells were analyzed by flow
cytometry.
To assay the kinetics of appearance of surface MHC class I, 293
cells were incubated for 60 min on ice with saturating amounts of
W6/32, then washed three times in PBS, replaced in warm culture
medium and incubated at 37uC for the length of time indicated in
the results section. To terminate further appearance of new surface
MHC-I, cells were rapidly cooled to 0uC. Finally, the newly
appeared surface MHC-I molecules were stained with PE-
conjugated W6/32, and the cells were analyzed by flow cytometry.
Western Blots
Total cell lysates were denatured in reducing sample buffer
(final concentration: 2% SDS, 72.5 mM Tris-HCl pH 6.8, 10%
glycerol, 0.2 M sodium 2-mercaptoethane-sulfonate, 0.002%
bromophenol blue), then sonicated and heated to 100uC for
5 minutes. Solubilized proteins equivalent to 2610
5 cells/20 ml
sample were separated by sodium dodecyl sulfate/polyacrylamide
gel electrophoresis (SDS/PAGE) on 4–12% gradient Bis-Tris
NuPage mini-gels with MOPS running buffer (Invitrogen).
Following electroblotting to polyvinylidene difluoride membranes
(Invitrogen) and blocking with I-Block (Tropix, Applied Biosys-
tems) in phosphate-buffered saline and 0.1% Tween-20 detergent,
specific proteins were detected by incubating the membranes with
primary antibodies at 4uC overnight. The 148.3 and 435.3 mouse
anti-TAP1 and TAP2 mAbs were used at 1/100 dilution of culture
supernatant, whilst the DA6.147 anti-HLA-DR was used at a 1/
250 dilution; the purified mouse mAbs, BZ.1, H68.4, 12CA5,
HC10, were used at 1 mg/ml; the rat anti-HA mAb was used at
50 ng/ml; and the goat antibody to calregulin, was used at 1 mg/
ml. Primary antibodies specifically bound to blotted proteins were
detected by incubation for 30 min with appropriate alkaline
phosphatase conjugated secondary antibodies, then were devel-
oped using a CDP-Star
TM detection kit (Tropix, Applied
Biosystems) and exposed to autoradiographic film. In one set of
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TM
immunoprecipitation dection reagent (Thermo Scientific) was used
at a 1/500 for 60 min to detect blots of immunoprecipitates being
probed with the HC10 mAb.
T cell function assays
The effector T cell clone, RAK, specific for BZLF1 and
restricted through HLA-B8, was generated as described elsewhere
[20]. Targets for the RAK clone were generated by transfection of
MJS cells (HLA-B8 type) with a BZLF1 expression plasmid with or
without a BILF1 expression plasmid. At 24 hr post-transfection,
recognition of target cells by the effector T cells was determined by
ELISA of IFN- c release using a standard protocol described
elsewhere [71]. Briefly, 10
4 effector T cells were incubated for
18 hr at 37uC in V-bottom microtest plate wells with 10
5 target
cells, then the supernatants were harvested for quantitation of
IFN-c by ELISA (Endogen) in accordance with the manufacturer’s
recommended protocol. Specificity control targets included HLA-
matched and HLA-mismatched EBV-transformed lymphoblastoid
cell lines (LCL), empty vector-transfected MJS cells, and empty
vector-transfected MJS cells pulsed with the RAKFKQLL
synthetic peptide.
LCLs transformed with a BZLF1
2 recombinant EBV (to
prevent induction of endogenous lytic cycle genes) were trans-
duced with control PLZRS-IRES-GFP or PLZRS-BILF1-IRES-
GFP retroviruses. These lines were used as targets in assays with a
panel of effector T cell clones specific for constitutively expressed
latent EBV genes, EBNA1, EBNA3A, LMP2 or BHRF1. The
effector T cell clone, HPV, was a CD8
+ line specific for EBNA1
and restricted through HLA-B35 [72]; clone YPL was a CD8
+ line
specific for EBNA3A and restricted through HLA-B35 [72]; clone
CLG was a CD8
+ line specific for LMP2A and restricted through
HLA-A2 [73]; clone PYY was a CD4
+ line specific for BHRF1
and restricted through DR4 (Kelly, G.L., Long, H.M. et al,
submitted for publication). Recognition of target cells by the
effector T cells was determined by ELISA of IFN- c release using a
standard protocol described elsewhere [71].
Metabolic Labeling, Immunoprecipitation, and Endo H
Digestion
Cells (10
7) were starved with 15 ml methionine-free DMEM
medium supplemented with 10% dialysed FCS for 1 h at 37uC,
then labeled for 15 min with 200 mCi of EasyTag Express
35S
protein labeling mix (NEN Life Science Products) in a final volume
of 1 ml. After two washes with chase medium (normal DMEM
medium supplemented with 10% FCS), the cells were resuspended
at 2610
6 cells/ml and chased at 37uC for the times indicated.
Samples containing 2610
6 cells were lysed in 400 ml of NP-40
buffer (0.5% Nonidet P-40, 5 mM MgCl2 and 50 mM Tris-HCl,
pH 7.5) with protease inhibitor cocktail (Sigma) at 4uC for 45 min.
Nuclei and insoluble debris were removed by centrifugation, and
the supernatants were precleared first with 1.2 ml of normal mouse
serum and 20 ml Dynabeads Protein A (Invitrogen) for 2 hr at
4uC, and then again with 20 ml Dynabeads Protein A and 20 ml
Dynabeads protein G at 4uC overnight. The precleared lysates
were immunoprecipitated for 2 hr with 6 ml of W6/32 Mini-
perm
TM culture supernatant and 20 ml Dynabeads Protein A plus
20 ml Dynabeads protein G, before washing the beads four times
with NET buffer (0.5% NP-40, 150 mM NaCl2, 5 mM EDTA
and 50 mM Tris-HCl, pH 7.5) and eluting by boiling in reducing
gel sample buffer for 5 min. For endoglycosidase H (Endo H)
treatment, 20 ml samples were incubated at 37uC for 2.5 hr with
2 ml G5 reaction buffer and 1.5 ml of Endo H enzyme (New
England Biolabs Inc.). For second-round precipitations, boiled
eluates were first diluted 10-fold with lysis buffer, then reprecip-
itated as above with either HC10 (MHC class I heavy chain) or
3F10 (anti-HA tag on BILF1). Finally, the samples were separated
by SDS-PAGE on 10% Bis-Tris NuPage mini-gels with MOPS
buffer (Invitrogen). After the gels were fixed and dried, they were
exposed to autoradiographic film.
Cold co-immunoprecipitations
For immunoprecipitations from whole cell lysates, 2610
6 cells
were lysed in 400 ml of NP-40 buffer with protease inhibitors and
were immunoprecipitated as above. Lysates were precipitated with
1 mg of either W6/32 (HLA-ABC), 12CA5 (HA-tag; BILF1) or
H68.4 (TfR) mAbs. Eluted samples were separated on 4–12% Bis-
Tris NuPage mini-gels with MOPS buffer, electroblotted to
polyvinylidene difluoride membranes and probed with antibodies
HC10 (anti- HLA class I heavy chain), H68.4 (anti-TfR) or 3F10
(anti-HA tag on BILF1). For the selective immunoprecipitation of
cell-surface surface molecules, 2610
6 cells were incubated for
60 min on ice with saturating amounts of W6/32, H68.4 or
12CA5, then washed three times in PBS. The cells were then lysed
in 400 ml of NP-40 buffer with protease inhibitors and immuno-
precipitated with 20 ml Dynabeads Protein A plus 20 ml
Dynabeads protein G.
Immunofluorescence staining of fixed cells
293-BILF1 cells were grown on glass slides coated with
fibronectin, and were treated with concanamycin A for 6 hrs.
For the confocal microscopy, the cells were rinsed with PBS and
fixed with 4% (w/v) paraformaldehyde in PBS for 20 min, then
permeabilized with 0.5% Triton X-100 in PBS for 5 min. For
conventional fluorescence microscopy, the cells were fixed and
permeabilized with methanol-acetone (1:1 vol:vol) for 15 min at
220uC. The slides were incubated with primary antibodies for
2h ra t3 7 uC, washed extensively in PBS, then incubated with
Alexa FluorH 488 goat anti-mouse IgG or Alexa FluorH 594 goat
anti-rat IgG secondary antibodies (Invitrogen) for 45 min. After
repeated washing the slides were mounted with vectashield
mounting medium with DAPI stain (Vector laboratories) and
analyzed with a Zies LSM510 laser scanning confocal microscope,
or with a Nikon E600 conventional fluorescence microscope.
Protease inhibitor assays
293 cells stably transduced with control or BILF1 retrovirus
were treated with Bafilomycin A1 (2 mM), concanamycin A
(50 nM), or leupeptin (200 mM) or MG132 (10 mM) for 20 hr. All
inhibitors were purchased from Sigma-Aldrich. Lysates from
2610
5 cell equivalents were separated by SDS/PAGE gel, and
analyzed by Western Blotting using antibodies specific for MHC
class I (HC10) and calregulin.
NFkB reporter assays
HEK293-NFkB-luc cells were seeded at 2610
5/ml in a 96-well
plate at 24 hr prior to transfection with a constitutively expressed
Renilla-luciferase reporter construct (phRL-TK, 70 ng/well, Pro-
mega) for normalizing transfection efficiency, together with BILF-
wild-type, BILF1-K122A mutant, or empty vector DNA (160 ng/
well). The Lipofectamine-2000 (Invitrogen) and DNA mix in Opti-
MEM medium was prepared according to the supplier’s
instructions, and 50 ml was then added to each well. Cell extracts
were generated after 48 h using Cell Culture Lysis Buffer
(Promega), and extracts were assayed for firefly luciferase and
Renilla-luciferase activity using the Luciferase Assay System and
Renilla Luciferase Assay System (Promega), respectively.
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